Home / Business and Economy / Symbiotec Pharmalab IPO: 42% Grey Market Premium Surge!
Symbiotec Pharmalab IPO: 42% Grey Market Premium Surge!
24 Aug
Summary
- IPO opens today, closes on August 26, 2026.
- Grey market premium signals a potential 42% listing gain.
- Price band set between ₹938 to ₹988 per equity share.
The Initial Public Offering (IPO) for Symbiotec Pharmalab Ltd. commenced its subscription period today, with investors able to bid until August 26, 2026. The company has established a price band of ₹938 to ₹988 per equity share for this offering.
Market sentiment appears highly positive, evidenced by a grey market premium (GMP) of ₹411, which translates to a projected listing gain of around 42%. This strong demand is occurring as the company aims to raise a total of ₹1,757 crore through the IPO.
The IPO structure includes both a fresh issue of shares and an Offer for Sale (OFS). Specifically, ₹150 crore is designated for the fresh issuance, while the remaining ₹1,607 crore will be realized through the OFS route.
Details regarding share allotment and listing are also emerging. The tentative date for finalising share allotment is August 27, 2026, with the proposed listing on both the BSE and NSE exchanges expected on September 1, 2026.
Symbiotec Pharmalab's business model is characterized by its significant export presence, with over 60 APIs supplied globally. The company's manufacturing capabilities are robust, featuring multiple facilities and a substantial R&D team, and its valuation is considered attractive compared to industry peers.
